A Phase 2,Open-Label, Single-Arm Study to Evaluate the Efficacy and SA
Research payments
$404,569
Through program year 2022, $404,569 in research payments was reported against A Phase 2,Open-Label, Single-Arm Study to Evaluate the Efficacy and SA, across 73 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $11,661 | 3 |
| 2021 | Research | $392,908 | 70 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Emily Prendergast Los Angeles, CA Named on 7 payments
- Panagiotis Konstantinopoulos Boston, MA Named on 6 payments
- Adam Elnaggar Cordova, TN Named on 6 payments
- Jean-Marie Stephan Chicago, IL Named on 5 payments
- Marilyn Huang Miami, FL Named on 5 payments
- Alberto Mendivil Newport Beach, CA Named on 4 payments
- Robert Holloway Orlando, FL Named on 4 payments
- Roisin O'Cearbhaill New York, NY Named on 4 payments
- Elizabeth Lokich Fall River, MA Named on 3 payments
- Daniel Sonnenburg Indianapolis, IN Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.